{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:52:46Z","timestamp":1787986366051,"version":"build-2784847793"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tenapanor is a minimally absorbed, small-molecule inhibitor of sodium\/hydrogen exchanger 3 and thus suppresses sodium absorption in the gastrointestinal tract. It is approved by the FDA for the treatment of hyperphosphatemia in dialysis patients. This randomized controlled trial evaluated its efficacy in the treatment of hyperphosphatemia and constipation in hemodialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety hemodialysis patients were randomized 1:1 to receive either tenapanor or standard care. Randomization was performed using a computer-generated sequence stratified by baseline serum phosphorus levels. The tenapanor group began treatment with a dosage of 10\u2009mg\/day, which was adjusted based on serum phosphorus levels. Primary outcomes were changes in serum phosphorus levels in the tenapanor and control groups and changes in stool consistency, assessed weekly using the Bristol Stool Form Scale (BSFS) in the tenapanor group. Secondary outcomes included laxative use and phosphate binder prescription patterns. Serum phosphorus levels, serum calcium, albumin, and related biochemical parameters were monitored every two weeks. Data were analyzed using intention-to-treat principles. This study was not blinded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 90 randomized participants, 69 completed the 23-week study. Tenapanor significantly improved stool consistency and resolved constipation (BSFS types 1\u20132) by week 5. A transient increase in loose stools (BSFS types 6\u20137) occurred early, with 10 participants discontinuing due to diarrhea. Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p\u2009&lt;\u20090.01). Serum phosphorus levels were decreased in both groups, with comparable control. Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tenapanor improves stool consistency, reduces laxative use, and provides effective phosphorus control in hemodialysis patients and represents a promising alternative to conventional phosphate binders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0319319","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:47:17Z","timestamp":1750168037000},"page":"e0319319","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-6777","authenticated-orcid":true,"given":"Naoki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akie","family":"Kabuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Sumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayanari","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mone","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-248X","authenticated-orcid":true,"given":"Yasumasa","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodoka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"4","key":"pone.0319319.ref001","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"GA Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"pone.0319319.ref002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","article-title":"Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?","volume":"39","author":"P Raggi","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"pone.0319319.ref003","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"WG Goodman","year":"2000","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0319319.ref004","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"SK Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0319319.ref005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"LA Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"pone.0319319.ref006","volume-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","author":"National Kidney Foundation","year":"2003"},{"issue":"4","key":"pone.0319319.ref007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","article-title":"Hyperphosphatemia management in patients with chronic kidney disease","volume":"24","author":"AM Shaman","year":"2016","journal-title":"Saudi Pharm J"},{"issue":"14","key":"pone.0319319.ref008","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"M Tonelli","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0319319.ref009","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","volume":"2011","author":"SD Navaneethan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pone.0319319.ref010","doi-asserted-by":"crossref","first-page":"2410389","DOI":"10.1080\/0886022X.2024.2410389","article-title":"Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis","volume":"46","author":"S Yu","year":"2024","journal-title":"Ren Fail"},{"issue":"1","key":"pone.0319319.ref011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12882-019-1334-x","article-title":"Interventional study to improve adherence to phosphate binder treatment in dialysis patients","volume":"20","author":"BJ Hjem\u00e5s","year":"2019","journal-title":"BMC Nephrol"},{"issue":"5","key":"pone.0319319.ref012","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ckj\/sfv062","article-title":"Possibility of lanthanum absorption in the stomach","volume":"8","author":"A Tonooka","year":"2015","journal-title":"Clin Kidney J"},{"issue":"16","key":"pone.0319319.ref013","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.2169\/internalmedicine.2398-18","article-title":"Frequent involvement of the duodenum with lanthanum deposition: a retrospective observational study","volume":"58","author":"M Iwamuro","year":"2019","journal-title":"Intern Med"},{"issue":"2","key":"pone.0319319.ref014","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1)","volume":"115","author":"WD Chey","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"456","key":"pone.0319319.ref015","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"AJ King","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"pone.0319319.ref016","doi-asserted-by":"crossref","first-page":"19100","DOI":"10.1038\/s41598-023-45080-9","article-title":"Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia","volume":"13","author":"F Koiwa","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0319319.ref017","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.ekir.2021.06.030","article-title":"Effect of tenapanor on phosphate binder pill burden in hemodialysis patients","volume":"6","author":"T Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"pone.0319319.ref018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10157-023-02406-1","article-title":"Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial","volume":"28","author":"M Nakayama","year":"2024","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"pone.0319319.ref019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.ajkd.2023.03.019","article-title":"Tenapanor for the treatment of hyperphosphatemia in japanese hemodialysis patients: a randomized phase 3 monotherapy study with an up-titration regimen","volume":"82","author":"M Fukagawa","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"pone.0319319.ref020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17425255.2023.2294937","article-title":"A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature","volume":"19","author":"D Curr\u00f2","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6722","key":"pone.0319319.ref021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/bmj.300.6722.439","article-title":"Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate","volume":"300","author":"LJ O\u2019Donnell","year":"1990","journal-title":"BMJ"},{"issue":"16","key":"pone.0319319.ref022","article-title":"Efficacy and complications of polyethylene glycols for treatment of constipation in children: a meta-analysis","volume":"93","author":"S-L Chen","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"pone.0319319.ref023","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00003088-200847090-00001","article-title":"Clinical pharmacokinetics of the phosphate binder lanthanum carbonate","volume":"47","author":"SJP Damment","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0319319.ref024","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"PE Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0319319.ref025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","volume":"52","author":"T Shigematsu","year":"2021","journal-title":"Am J Nephrol"},{"key":"pone.0319319.ref026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1744-9987.12228","article-title":"Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride","volume":"18","author":"S Gen","year":"2014","journal-title":"Ther Apher Dial"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:47:30Z","timestamp":1750168050000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319319"}},"subtitle":[],"editor":[{"given":"Tarek Samy","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319319","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.02.25321552","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}